Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607150 | 0.94 | NOS1 (0.45) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4523926 | 0.89 | NOS1 (0.44) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3612784 | 0.85 | NOS1 (0.42) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3924318 | 0.85 | NOS1 (0.46) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3611916 | 0.84 | NOS1 (0.42) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3614268 | 0.83 | MPO (0.37) | NOS1KDM4EDHFRMAPT | |
| SCHEMBL3605603 | 0.82 | NOS1 (0.41) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3614661 | 0.82 | NOS1 (0.41) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4526538 | 0.82 | ALDH1A1 (0.46) | NOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3924335 | 0.81 | NOS1 (0.44) | NOS1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048559-A1 | PYRIDO(3,2-d)PYRIDMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | Gilead Science, Inc (US) | 2010-02-25 | — | — | US | claimed |
| US-8637531-B2 | Pyrido(3,2-d)pyridmidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100048559-A1 | PYRIDO(3,2-d)PYRIDMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | Gilead Science, Inc (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2008077650-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | NOS1 1505/4885PDE4A 366/4885PDE4B 377/4885 |
| US-20100048559-A1 | PYRIDO(3,2-d)PYRIDMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, PLPBP, PDXK | NOS1 424/4885PDE4A 843/4885PDE4B 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.